CoChat

A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy

Open access
Kong, Deok-Hoon, Kim, Mi, Jang, Ji, Na, Hee-Jun, Lee, Sukmook · 2017 · International Journal of Molecular Sciences

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Tumor angiogenesis is a key event that governs tumor progression and metastasis. It is controlled by the complicated and coordinated actions of pro-angiogenic factors and their receptors that become upregulated during tumorigenesis. Over the past several decades, vascular endothelial growth factor (VEGF) signaling has been identified as a central axis in tumor angiogenesis. The remarkable advent of recombinant antibody technology has led to the development of bevacizumab, a humanized antibody that targets VEGF and is a leading clinical therapy to suppress tumor angiogenesis. However, despite the clinical efficacy of bevacizumab, its significant side effects and drug resistance have raised concerns necessitating the identification of novel drug targets and development of novel therapeutics to combat tumor angiogenesis. This review will highlight the role and relevance of VEGF and other potential therapeutic targets and their receptors in angiogenesis. Simultaneously, we will also cover the current status of monoclonal antibodies being developed to target these candidates for cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms18081786

Cites

Statistics

Figures

Figure 1 Mechanisms of action of monoclonal antibodies targeting VEGF, PDGF, HGF, Ang, and their receptors for suppressing tumor growth and angiogenesis. Under pathological conditions, including hypoxia, most tumor cells and/or adjacent cells upregulate the expression of many angiogenic factors, including VEGF, PDGF, HGF, and Ang, and secrete them within the tumor microenvironment. When these molecules bind their cognate receptors, receptor dimerization and autophosphorylation stimulate downstream signaling molecules including phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/v-Akt murine thymoma viral oncogene (Akt) and MAPK (dash lines) for the promotion of tumor growth and angiogenesis. Currently, most antibody therapeutics are being developed to block the interaction between agonists and their receptors (T arrows).
Figure 1 Mechanisms of action of monoclonal antibodies targeting VEGF, PDGF, HGF, Ang, and their receptors for suppressing tumor growth and angiogenesis. Under pathological conditions, including hypoxia, most tumor cells and/or adjacent cells upregulate the expression of many angiogenic factors, including VEGF, PDGF, HGF, and Ang, and secrete them within the tumor microenvironment. When these molecules bind their cognate receptors, receptor dimerization and autophosphorylation stimulate downstream signaling molecules including phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/v-Akt murine thymoma viral oncogene (Akt) and MAPK (dash lines) for the promotion of tumor growth and angiogenesis. Currently, most antibody therapeutics are being developed to block the interaction between agonists and their receptors (T arrows).CC BY · PubMed Central
Figure 2 Dual mode of action of a monoclonal antibody targeting the CLEC14a (C-type domain family 14 member) CTLD (C-type lectin-like domain) in cancer. (A) In tumor angiogenesis, the CLEC14a CTLD (red) plays a key role in mediating endothelial cell-cell contacts. When a targeting antibody binds to the CTLD of CLEC14a on tumor vessels, endothelial cell-cell contacts are inhibited, resulting in inhibition of tumor angiogenesis; (B) Simultaneously, binding of the antibody to CLEC14a on endothelial cells induces internalization of CLEC14a and eventually leads to its downregulation. These molecular mechanisms are important for suppressing CLEC14a-mediated tumor angiogenesis.
Figure 2 Dual mode of action of a monoclonal antibody targeting the CLEC14a (C-type domain family 14 member) CTLD (C-type lectin-like domain) in cancer. (A) In tumor angiogenesis, the CLEC14a CTLD (red) plays a key role in mediating endothelial cell-cell contacts. When a targeting antibody binds to the CTLD of CLEC14a on tumor vessels, endothelial cell-cell contacts are inhibited, resulting in inhibition of tumor angiogenesis; (B) Simultaneously, binding of the antibody to CLEC14a on endothelial cells induces internalization of CLEC14a and eventually leads to its downregulation. These molecular mechanisms are important for suppressing CLEC14a-mediated tumor angiogenesis.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 222 · Cited by 161

Research works printed but not linked: 1

  1. Andre, 2013, Aflibercept (zaltrap (®)) approved in metastatic colorectal cancer, Bull Cancer, 100, 1023

Metadata

Authors
Kong, D.-H., Kim, M., Jang, J., Na, H.-J., & Lee, S.
Affiliations
Scripps Korea Antibody Institute (KR)
Corresponding author
  • Na, Hee-Jun
  • Lee, Sukmook
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2017-08-17
Volume
18
Issue
8
Pages
1786
ISSN
1422-0067 (ISSN-L)
OpenAlex
W2748749383
Cited by
161
References
222
Citations by year
2026: 3 · 2025: 10 · 2024: 16 · 2023: 12 · 2022: 22 · 2021: 16 · 2020: 33 · 2019: 31 · 2018: 15 · 2017: 2
FWCI
2.06
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • the Scripps Korea Antibody Institute (10TS03)
  • the Bio & Medical Technology Development Program of the National Research Foundation (2015M3A9 D9074279)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
Keywords
anti-angiogenic therapy, tumor angiogenesis, VEGF signaling, monoclonal antibodies, bevacizumab, VEGF receptors, humanized monoclonal antibody, drug resistance, novel therapeutic targets, cancer therapy
MeSH terms
Bevacizumab, Humans, Immunotherapy, Neoplasms, Neovascularization, Pathologic, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Antibodies, Monoclonal, Humanized, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy. https://app.cochat.ai/papers/10.3390/ijms18081786
The paper
Kong, D.-H., Kim, M., Jang, J., Na, H.-J., & Lee, S. (2017). A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms18081786

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.